ACN Newswire

2024-10-23 15:43

Stable S&P rating supports Fosun's globalization and innovation

HONG KONG, Oct 23, 2024 - (ACN Newswire) - HK equity market experienced snap adjustment rally in September, and is now entering stock picking phase before new round of catalyst arrives. Now is the period when investors explore resilient names whose fundamentals is robust enough to weather market turbulence. Fosun International (00656) fits into this category, with its continuous efforts on innovation and globalization, combined with solid delivery on financial result and attractive valuation.

Fosun International is one of the few leading enterprises rooted in China with global operational capabilities. Since its establishment in 1992, Fosun International has built an industrial presence in more than 35 countries and regions worldwide, continually enhancing its global operational capabilities. It has now become a global innovation-driven consumer group.

Enhancing innovation capabilities while delivering robust global operational capabilities

Over past decades, Fosun has been enhancing and deepening its globalization capabilities via launching new products and advancing its international operation.

Take pharmaceutical products for example, the biosimilar HANQUYOU has pioneered the international market expansion for Fosun. With licensing agreements covering approximately 100 countries and regions and marketing approvals in 48 countries and regions, HANQUYOU has become the China-developed biosimilar with the most marketing approvals.

Thanks to the overseas expansion of biosimilars, Fosun has not only established its reputation internationally, but has also gained experience in the globalization of first-in-class drugs. HANZISHUANG, the world's first anti-PD-1 monoclonal antibody approved for the first-line treatment of small cell lung cancer (SCLC) independently developed by Shanghai Henlius, is an example of success. Fosun's overseas expansion of biopharmaceutical has resulted in the advancement of both first-in-class drugs and biosimilars. In 2023, Shanghai Henlius became the first first-in-class pharmaceutical company among its peers to achieve profitability through product sales.

In terms of operations, Fosun International focuses on organization evolution and global resource integration. By leveraging regional advantages, it establishes a profound industrial presence and localized operations to continuously benefit its industries and brands.

For example, in the tourism sector, Fosun Tourism Group (FTG) has achieved remarkable growth through its unique asset-light operating model, global presence and global operations. FTG's subsidiary Club Med, which operates 67 resorts worldwide, achieved a record-high business volume of RMB8.89 billion in the first half of 2024, representing a year-on-year increase of 10.3%. Its business in the Europe, Middle East and Africa (EMEA) region and the Americas continued to grow, while its business in Asia-Pacific region recovered significantly. In May 2024, Club Med signed an agreement in Oman for the launch of its first resort in the Middle East.

Notably, there are very few domestic tourism companies that adopt an asset-light operating model and are equipped with global operational capabilities, making FTG a benchmark for the development of China's tourism industry. In addition, Fosun International continues to drive innovation and optimization in the consumption and insurance sectors, making positive impact on China's economic growth and industrial upgrades.

As Fosun International enhances its focus on its "products + operations", its globalization capabilities are gradually bearing fruit, while its innovation capabilities are further developing. This approach has effectively strengthened its advantages in core industries such as tourism, consumption, pharmaceuticals, and insurance, garnering market optimism.

S&P affirms Fosun International's "stable" rating outlook, noting that creditworthiness remains steady

Recently, Fosun International received further recognition in the international rating agencies. On 21 October, S&P released a report acknowledging Fosun's successful asset divestment and debt reduction efforts, assigning it a stable rating outlook.

Specifically, S&P acknowledges the improvement of Fosun's liability structure, noting that bank loans now account for 73% of the holding company's debts, up from 46% in mid-2022. Fosun International completed a USD888 million offshore syndicate in September 2024, reflecting an increase in both bank participation and size compared to the syndicate due in May. S&P regards this as a clear evidence of recovery in offshore bank refinancing channels.

The smooth access to financing channels reflects the confidence of domestic and international financial institutions in Fosun's financial position and business strategy. This not only reduces Fosun's reliance on public market financing but also allows for better support of liquidity management and greater flexibility to manage the pace of future asset divestment. S&P expects Fosun's asset recycling could continue to drive further debt reduction.

The positive evaluation from S&P affirms Fosun International's strong execution of its globalization and innovation capabilities. Over the past two years, the remarkable improvement in its balance sheet and enhanced financial resilience have been evident. Additionally, this endorsement reinforces the company's investment value.

Overall, as the outlook for the Chinese economy improves, especially with the implementation of key policy initiatives, the Hong Kong stock market holds significant growth potential. Thanks to its global presence, integrated innovation, and asset-light operating strategy, Fosun International is enhancing performance certainty and strengthening its financial resilience against risks. As its global operations continue to expand, industry-leading advantages strengthen, and the benefits of technology innovation accelerate, Fosun is poised to capitalize on the next wave of growth in the Hong Kong stock market.



Copyright 2024 ACN Newswire. All rights reserved. www.acnnewswire.com

人氣文章
最近7天
1
高息定存 | 6個月港元定存3.8厘新高,188日快閃優惠3.68厘
2
高息定存 | 富邦推快閃定存優惠3個月3.9厘,華僑188日3.68厘
3
高息定存 | 工銀亞洲推3個月5厘息搶新客,招商永隆推快閃優惠
4
【FOCUS】零售寒冬襲京滬港,逆市奇葩值借鏡
5
港股 | 蕭猷華:恒指料退守至18600點,宜逢低吸納
6
神州經脈 | 換手機可獲政府補貼,政策利率將降,滬指周挫逾5%
7
內銀股 | 人行再提擇機減息降準,內銀獲中金唱好,應該點部署?
8
神州經脈 | PMI遜預期,滬指全年止跌回升,人幣年度貶幅擴
9
大國博弈 | 【FOCUS】騰訊商湯寧德重挫,CMC清單劍指軍民融合
10
回顧展望-人幣走貶 | 關稅殺到,先貶為敬,人幣明年勢見7.5
11
新股掛牌 | 布魯可首日掛牌升41%,每手賺7395元
12
加州山火 | 【FOCUS】洛杉磯烈火焚城,天災背後藏人禍
13
高息定存 | 一周高息合集,恒生1個月定存4厘,工銀亞洲3個月最高5厘
14
回顧展望-A股自強 | 憧憬國策利好,機構對明年股市走勢樂觀
15
高息定存 | 渣打特選客6個月3.48厘,建行亞洲推1個月6.18厘高息吸客
16
高息定存 | 花旗3個月港元定存息加至4厘,信銀國際3.88厘
17
一本萬利 | 2025年的五個「勿」(有片)
18
高息定存 | 一周高息合集,銀行高息吸客,低門檻10萬享6.18厘,3個月最高5厘
19
港股 | 蕭猷華:恒指春節前目標21500點
20
互聯支付 | 黃俊碩:轉數快與IBPS互聯支付所產生的發展契機
21
神州經脈 | 基金賣股票據報受限,滬指連跌四日,人行穩匯率
22
專訪|洪灝:美股更大跌幅在前面,恐需習慣4%通脹(有片)
23
英偉達 | DeepSeek衝擊AI晶片行業結構 英偉達暴跌仍未急抄底
24
易經看世界 | 從乙巳年立春八字看香港前景:哪行業當旺?哪行業運滯?(有片)
25
習近平應約與特朗普通電話,特:冀盡快與習見面
26
財政預算案2025 | 羅兵咸料本財年財赤948億,財政儲備降至紀錄新低
27
加州山火 | 美國洛杉磯大火失控,被迫撤離人數增至18萬
28
賣地計劃 | 政府今季推一幅東涌住宅地涉745伙,全年供應不達標
29
高息定存 | 一周高息合集,部分銀行逆市加息,南商3個月加至3.8厘
30
【FOCUS】去年貿易順差破紀錄,中國擴消費增緊迫感
專業版
HV2
精裝版
SV2
串流版
IQ 登入
強化版
TQ
強化版
MQ

【etnet 30周年】多重慶祝活動一浪接一浪,好禮連環賞!

【蛇年行大運 新年好賞「飾」】etnet賞太歲開運趨吉避凶神器

etnet榮獲HKEX Awards 2023 「最佳證券數據供應商」大獎

大國博弈

貨幣攻略

說說心理話

聖誕新年特輯

Watch Trends 2024

北上食買玩

Art Month 2024

秋天養生食療

山今養生智慧

輕鬆護老